Office

Level 9, Suite 1, 68 Pitt Street,
Sydney, NSW, 2000, Australia

+61 (02) 8964 7401

info@actinogen.com.au

Social Media

Actinogen Medical logo

“Focused on the treatment of Alzheimer’s disease
and cognitive impairment.”

Actinogen Medical is a publicly listed (ASX: ACW) clinical-stage biotechnology company undertaking a focused and differentiated approach for treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production.

Actinogen Medical is developing Xanamem™, a novel drug for Alzheimer’s disease, which has been specifically designed to block the production of cortisol in the brain.

Find out more

Actinogen Medical has successfully completed all the necessary early phase studies to confirm that Xanamem™ is well tolerated with an acceptable safety profile.

Actinogen Medical is well advanced with plans for the Phase II “XanADu” efficacy and safety study for mild Alzheimer’s disease patients in the second half of 2016. This study will be run in Australia, the United Kingdom, and the United States with appropriate regulatory approvals.

Find out more

“Positive trial results confirm Xanamem™ is effectively delivered to the brain.”

– Dr. Bill Ketelbey, 29 September, 2015

December

01 Dec 2015 – Investor Update

November

17 Nov 2015 – Change of Company Name
12 Nov 2015 – Results of AGM
12 Nov 2015 – CEO’s AGM Presentation
12 Nov 2015 – Chairman’s AGM Address
06 Nov 2015 – Release of Securities from Voluntary Escrow

October
September
August
July
June
May
April

30 Apr 2015 – Share Purchase Plan
28 Apr 2015 – Change in Substantial Shareholding
27 Apr 2015 – Change in Substantial Shareholding
24 Apr 2015 – Ethics Approval Granted for Second Stage Phase I
24 Apr 2015 – Successful Capital Raising
24 Apr 2015 – Appendix 4C: Quarterly
22 Apr 2015 – Trading Halt
16 Apr 2015 – Clinical Trial Update
16 Apr 2015 – XCAB Conference Call Transcript
15 Apr 2015 – Investor Update
13 Apr 2015 – EU Patent Granted
13 Apr 2015 – Investor Presentation
13 Apr 2015 – XCAB Conference Call

March
February
January
December

18 Dec 2014 – ACW Board Changes
18 Dec 2014 – Appendix 3Z
18 Dec 2014 – Appendix 3X
15 Dec 2014 – Notice 708A
15 Dec 2014 – Appendix 3B
15 Dec 2014 – ACW Appoints Dr. Bill Ketelbey as CEO

View All Announcements

Subscribe to our newsletter

Are you an Investor?  Yes